Moleculin Biotech
MBRX
MBRX
23 hedge funds and large institutions have $1.78M invested in Moleculin Biotech in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-1
Holders Change %
-4.17%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$294K |
| 2 |
AC
Armistice Capital
New York
|
+$179K |
| 3 |
Renaissance Technologies
New York
|
+$93.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89.6K |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
+$40.4K |
Top Sellers
| 1 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$170K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$21K |
| 4 |
VF
Virtu Financial
New York
|
-$13K |
| 5 |
BlackRock
New York
|
-$2.63K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$21K | -224 | Closed |
|
|
VF
27
Virtu Financial
New York
| – | -$13K | -138 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$1K | -9 | Closed |
|